Gadolinium‐modulated 19F signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging

Recent advances in the design of fluorinated nanoparticles for molecular magnetic resonance imaging (MRI) have enabled specific detection of 19F nuclei, providing unique and quantifiable spectral signatures. However, a pressing need for signal enhancement exists because the total 19F in imaging voxels is often limited. By directly incorporating a relaxation agent, gadolinium (Gd), into the lipid monolayer that surrounds the perfluorocarbon (PFC), a marked augmentation of the 19F signal from 200‐nm nanoparticles was achieved. This design increases the magnetic relaxation rate of the 19F nuclei fourfold at 1.5 T and effects a 125% increase in signal—an effect that is maintained when they are targeted to human plasma clots. By varying the surface concentration of Gd, the relaxation effect can be quantitatively modulated to tailor particle properties. This novel strategy dramatically improves the sensitivity and range of 19F MRI/MRS and forms the basis for designing contrast agents capable of sensing their surface chemistry. Magn Reson Med 60:1066–1072, 2008. © 2008 Wiley‐Liss, Inc.

[1]  P. Stratta,et al.  Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. , 2008, Current medicinal chemistry.

[2]  Rika Takikawa,et al.  [In-vivo visualization of gene expression using magnetic resonance imaging]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[3]  T. Meade,et al.  The synthesis and in vitro testing of a zinc-activated MRI contrast agent , 2007, Proceedings of the National Academy of Sciences.

[4]  A. Kenwright,et al.  Responsive fluorinated lanthanide probes for 19F magnetic resonance spectroscopy. , 2007, Chemical communications.

[5]  S. Caruthers,et al.  19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  Garry E. Kiefer,et al.  Imaging of Vx‐2 rabbit tumors with ανβ3‐integrin‐targeted 111In nanoparticles , 2007 .

[7]  S. Caruthers,et al.  Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. , 2007, International journal of cancer.

[8]  Shelton D Caruthers,et al.  Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. , 2007, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[9]  Ralph Weissleder,et al.  Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. , 2006, Radiology.

[10]  Shelton D Caruthers,et al.  In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.

[11]  Eric T Ahrens,et al.  In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.

[12]  P. Winter,et al.  Improved Paramagnetic Chelate for Molecular Imaging with MRI , 2005 .

[13]  J. McNab,et al.  Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[14]  Patrick J. Gaffney,et al.  Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .

[15]  Samuel A Wickline,et al.  Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.

[16]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[17]  K. Scheffler,et al.  Principles and applications of balanced SSFP techniques , 2003, European Radiology.

[18]  Sheng-Kwei Song,et al.  Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.

[19]  Shelton D Caruthers,et al.  Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. , 2003, Circulation.

[20]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[21]  Xiaobing Fan,et al.  Effect of carbogen on tumor oxygenation: combined fluorine-19 and proton MRI measurements. , 2002, International journal of radiation oncology, biology, physics.

[22]  D. Cafiso,et al.  Perfluorooctyl bromide has limited membrane solubility and is located at the bilayer center. Locating small molecules in lipid bilayers through paramagnetic enhancements of NMR relaxation. , 2002, Journal of medicinal chemistry.

[23]  P. Winter,et al.  Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. , 2002, Academic radiology.

[24]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[25]  Peter Caravan,et al.  Enzyme-Activated Gd3+ Magnetic Resonance Imaging Contrast Agents with a Prominent Receptor-Induced Magnetization Enhancement. , 2001, Angewandte Chemie.

[26]  P. Antich,et al.  Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. , 2001, International journal of radiation oncology, biology, physics.

[27]  S. Laurent,et al.  Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.

[28]  P. Antich,et al.  Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. , 1997, Magnetic resonance imaging.

[29]  P. Gaffney,et al.  Evaluation of the Fibrin Binding Profile of two Anti-fibrin Monoclonal Antibodies , 1996, Thrombosis and Haemostasis.

[30]  P. Antich,et al.  A Comparison of Three Commercial Perfluorocarbon Emulsions as High-Field 19F NMR Probes of Oxygen Tension and Temperature , 1995 .

[31]  Stephen R. Thomas,et al.  Evaluation of the influence of the aqueous phase bioconstituent environment on the F‐19 T1 of perfluorocarbon blood substitute emulsions , 1994, Journal of magnetic resonance imaging : JMRI.

[32]  P. Antich,et al.  Tumor oxygen tension: measurement using Oxygent as a 19F NMR probe at 4.7 T. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[33]  S. Flaim Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[34]  R. Hurd,et al.  19F relaxation rate enhancement and frequency shift with Gd-DTPA. , 1989, Investigative radiology.